The former CEO of Alexion Pharmaceuticals and chief scientific officer at bluebird bio have raised $150 million to launch a new investment and manufacturing firm for cell and gene therapies.

The new company, ElevateBio, will found and invest in companies that are developing treatments that directly affect a person’s cells and genes. F2 Capital and one of MPM Capital’s funds co-led the Series A financing round that closed this week (ElevateBio’s founders are currently partners at the two investment…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/05/13/ex-alexion-bluebird-execs-launch-investment-and.html?ana=RSS&s=article_search